Synthesis and Distribution of Drugs of Abuse and Related Compounds

Solicitation description

INTRODUCTION PURSUANT TO FAR Subpart 5.2—Synopses of Proposed Contract Actions, THIS IS A NOTICE OF A PROPOSED CONTRACT ACTION. THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE MODIFICATION UNDER CONTRACT NO. 75N95022D00016 WITH RESEARCH TRIANGLE INSTITUTE. The National Institute on Drug Abuse (NIDA) Division of Therapeutics and Medical Consequences (DTMC) at the National Institutes of Health (NIH) intends to modify the Single Award Indefinite Delivery, Indefinite Quantity (IDIQ) Contract No. 75N95022D00016 “Synthesis and Distribution of Drugs of Abuse and Related Compounds” to increase the Single Award IDIQ maximum by $3,718,289 from $14,004,330 to $17,722,619 during the five (5) year ordering period from June 9, 2022 to June 8, 2027; there are no other changes. The increase to the IDIQ maximum will allow for the continuation of work begun under the Synthesis and Distribution of Drugs of Abuse and Related Compounds contract and prevent any delays or disruption of support services for scientific research working on problems of substance use and drug dependence with authentic and pure supplies of controlled drugs and research chemicals essential for ongoing and upcoming pre-clinical and clinical trials while a new contract is properly planned and competed. To support efforts in addressing the national public health crisis from substance use, NIDA through this contract modification also addresses an increased need for drug product to support clinical trials. The increase in the IDIQ maximum will, therefore, allow for the continuation of work initiated under this contract in addition to purchasing drug product to support new and ongoing clinical trials. The contract provides contract support services in the following areas to: Produce and distribute labeled and unlabeled drugs of abuse and other research compounds to researchers as approved by the NIDA COR; Analyze, test, and maintain the purity of drugs of abuse and other chemical compounds in the NIDA drug supply inventory; replenish existing drug supply inventory with synthesis or acquisition of depleted drug/chemical substances; ; identify, acquire, store and update the drug supply inventory with newly discovered chemical compounds useful for drug abuse research; and use, maintain, and update the NIDA drug supply database, known as Drug Inventory Supply Control System (DISCS). NORTH AMERICAN INDUSTRY CLASSIFICATION SYSTEM (NAICS) CODE The intended procurement is classified under NAICS code 541715 with a small business size standard of 1,000 employees REGULATORY AUTHORITY The resultant modification will include all applicable provisions and clauses of the Revolutionary FAR Overhaul (RFO) Initiative, in accordance with Executive Order 14275 and OMB Memorandum M-25-26. STATUTORY AUTHORITY This modification is conducted under the authority of 10 U.S.C. 3204(a)(1) or 41 U.S.C. 3304(a)(1) and in accordance with FAR 6.103-1 Only one responsible source and no other supplies or services will satisfy...

Similar opportunities

Other open SAM.gov opportunities under the same NAICS, prioritizing the same buying agency.

Data this profile does NOT cover

• No likely incumbent surfaced; the solicitation number did not prefix-match any award in the FPDSAward window.